Last reviewed · How we verify

Changchun BCHT Biotechnology Co. — Portfolio Competitive Intelligence Brief

Changchun BCHT Biotechnology Co. pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Herpes Zoster Vaccine, Live Herpes Zoster Vaccine, Live marketed Live attenuated vaccine Immunology / Infectious Disease
DTacP DTacP phase 3 Immunotoxin Oncology
live attenuated zoster vaccine live attenuated zoster vaccine phase 3 Immunology
DTacP-IPV/Hib DTacP-IPV/Hib phase 3 Combination vaccine Immunology / Infectious Disease Prevention

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. PT Bio Farma · 2 shared drug classes
  2. Serum Institute of India Pvt. Ltd. · 2 shared drug classes
  3. Jiangsu Province Centers for Disease Control and Prevention · 2 shared drug classes
  4. Merck Sharp & Dohme LLC · 2 shared drug classes
  5. Sanofi · 2 shared drug classes
  6. Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
  7. GlaxoSmithKline · 2 shared drug classes
  8. Sinovac Biotech Co., Ltd · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Changchun BCHT Biotechnology Co.:

Cite this brief

Drug Landscape (2026). Changchun BCHT Biotechnology Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/changchun-bcht-biotechnology-co. Accessed 2026-05-16.

Related